研究单位：[1]CSPC ZhongQi Pharmaceutical Technology Co., Ltd.[2]Harbin Medical University[3]Anhui Provincial Hospical,Hefei,Anhui,China,230000[4]Cancer Center Sun Yat-sen University,Guozhou,Guodong,China,510060[5]Affiliated Hospital of Hebei University,Baoding,Hebei,China,071030[6]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050000[7]Tangshan People's Hospital,Tangshan,Hebei,China,063000[8]Xingtai People's Hospital,Xingtai,Hebei,China,054000[9]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150008[10]Daqing People's Hospital,Daqing,Helongjiang,China,163316[11]Cancer Hospital of Jiamusi City,Jiamusi,Helongjiang,China,154007[12]The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,China,453100[13]Cancer Hospital of Henan Province,Zhengzhou,Henan,China,450008[14]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[15]Henan Provincial People's Hospital,Zhenzhou,Henan,China,450008[16]Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[17]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China,430071[18]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[19]Changsha Kexin Cancer Hospital,Changsha,Hunan,China,413002[20]Yiyang Central Hospital,Yiyang,Hunan,China,413002[21]The third Hospital of Nanchang,Nanchang,Jiangxi,China,330000[22]The second hospital of Jinlin University,Changchun,Jinlin,China,130041[23]The second hospital of Dalian Medical University,Dalian,Liaoning,China,116023[24]The First Affiliated Hospital of Jinzhou Medical University,Jinzhou,Liaoning,China,121000[25]The First hospital of China Medical University,Shenyang,Liaoning,China,110000[26]Shanxi Provincial Cancer Hospital,Taiyuan,Shanxi,China,0300001[27]Yuncheng Central Hospital,Yuncheng,Shanxi,China,044000[28]Sichuan Cancer Hospital & Institute,Chengdu,Sichuan,China,610041[29]The second people's hospital of neijiang,Neijiang,Sichuan,China,641100[30]Affiliated tumor Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China,830011[31]The First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang,China,830011
研究目的：
This is a multicenter, open-label, single-arm, phase II study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in patients with advanced HER2 negative breast cancer.
